Hepatitis C in Iceland: a milestone for global elimination
- PMID: 34171268
- DOI: 10.1016/S2468-1253(21)00182-5
Hepatitis C in Iceland: a milestone for global elimination
Conflict of interest statement
OD received grants from Gilead, AbbVie, and Merck Sharp & Dohme. HM received personal fees for participation in advisory board for Gilead, AbbVie, and Merck Sharp & Dohme. KBK declares no competing interests.
Comment on
-
Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study.Lancet Gastroenterol Hepatol. 2021 Aug;6(8):628-637. doi: 10.1016/S2468-1253(21)00137-0. Epub 2021 Jun 23. Lancet Gastroenterol Hepatol. 2021. PMID: 34171267
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical